More mice or a better mouse trap? Reflections on primary outcome indices in illicit drug dependence treatment research

Addiction

Volumn 107, Issue 4, 2012, Pages 723-724

  Donovan, Dennis M ^a,b  

^a Alcohol and Drug Abuse Institute   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Clinical trials; Drug dependence; Outcome measures; Substance abuse treatment; Substance use assessments

Indexed keywords

STREET DRUG;

ADDICTION; CLINICAL TRIAL (TOPIC); HUMAN; MEDICAL RESEARCH; METHODOLOGY; NOTE;

BIOMEDICAL RESEARCH; CLINICAL TRIALS AS TOPIC; HUMANS; STREET DRUGS; SUBSTANCE-RELATED DISORDERS;

EID: 84857612233     PISSN: 09652140     EISSN: 13600443     Source Type: Journal    
DOI: 10.1111/j.1360-0443.2012.03784.x     Document Type: Note

References (14)

1. Bühringer G. The mountain roared and brought forth a mouse: comments on the results of an expert panel on standardization of drug dependence treatment trial outcome variables. Addiction 2012; 107: 722-3.
2. Del Boca F. K., Darkes J. 'Nothing is more practical than a good theory': outcome measures in addictions treatment research. Addiction 2012; 107: 719-20.
3. Uchtenhagen A. How to measure outcome in clinical trials of substance abuse treatment. Addiction 2012; 107: 720-1.
4. Donovan D. M., Bigelow G. E., Brigham G. S., Carroll K. M., Cohen A. J., Gardin J. G. etal. Primary outcome indices in illicit drug dependence treatment research: systematic approach to selection and measurement of drug use end-points in clinical trials. Addiction 2012; 107: 694-708.
5. Tiffany S. T., Friedman L., Greenfield S. F., Hasin D. S., Jackson R. Beyond drug use: a systematic consideration of other outcomes in evaluations of treatments for substance use disorders. Addiction 2012; 107: 709-18.
6. Miller P. G., Miller W. R. What should we be aiming for in the treatment of addiction? Addiction 2009; 104: 685-6.
7. Trivedi M. H., Greer T. L., Potter J. S., Grannemann B. D., Nunes E. V., Rethorst C. etal. Determining the primary endpoint for a stimulant abuse trial: lessons learned from STRIDE (CTN 0037). Am J Drug Alcohol Abuse 2011; 37: 339-49.
8. Donovan D. M., Mattson M. E., Cisler R. A., Longabaugh R., Zweben A. Quality of life as an outcome measure in alcoholism treatment research. J Stud Alcohol 2005; suppl 15: 119-39.
9. LoCastro J. S., Youngblood M., Cisler R. A., Mattson M. E., Zweben A., Anton R. F. etal. Alcohol treatment effects on secondary nondrinking outcomes and quality of life: the COMBINE study. J Stud Alcohol Drugs 2009; 70: 186-96.
10. Laudet A. B. The case for considering quality of life in addiction research and clinical practice. Addict Sci Clin Pract 2011; 6: 44-55.
11. Longabaugh R., Donovan D. M., Karno M. P., McCrady B. S., Morgenstern J., Tonigan J. S. Active ingredients: how and why evidence-based alcohol behavioral treatment interventions work. Alcohol Clin Exp Res 2005; 29: 235-47.
12. Morgenstern J., Frey R. M., McCrady B. S., Labouvie E., Neighbors C. J. Examining mediators of change in traditional chemical dependency treatment. J Stud Alcohol 1996; 57: 53-64.
13. Bühringer G., Wittchen H. U. Understanding addiction-mediators and moderators of behaviour change processes: an introduction. Int J Methods Psychiatr Res 2008; 17: S1-3.
14. Rehm J. Key future research questions on mediators and moderators of behaviour change processes for substance abuse. Int J Methods Psychiatr Res 2008; 17: S83-7.